SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059576
Filing Date
2024-05-14
Accepted
2024-05-14 16:15:46
Documents
58
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tnya-20240331.htm   iXBRL 10-Q 1660214
2 EX-31.1 tnya-ex31_1.htm EX-31.1 20279
3 EX-31.2 tnya-ex31_2.htm EX-31.2 20385
4 EX-32.1 tnya-ex32_1.htm EX-32.1 12981
  Complete submission text file 0000950170-24-059576.txt   6041737

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20240331.xsd EX-101.SCH 811230
62 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20240331_htm.xml XML 901388
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40656 | Film No.: 24944556
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)